Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 13/20 | 0.56 |
| ▸ | LPAR3 | Q9UBY5 | 13/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.56 |
| ▸ | LPAR6 | P43657 | 7/20 | 0.45 |
| ▸ | LPAR4 | Q99677 | 7/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 7/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 4/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12357161 | 0.90 | LPAR1 (0.62) | LPAR1LPAR3LPAR2LPAR6LPAR4 | |
| SCHEMBL13352075 | 0.88 | LPAR1 (0.57) | LPAR1LPAR3LPAR2RECQLTLR2 | |
| SCHEMBL12349096 | 0.88 | LPAR1 (0.57) | LPAR1LPAR3LPAR2RECQLTLR2 | |
| SCHEMBL12357162 | 0.87 | LPAR1 (0.58) | LPAR1LPAR3LPAR2LPAR6LPAR4 | |
| SCHEMBL12349100 | 0.86 | LPAR1 (0.57) | LPAR1LPAR3LPAR2LPAR6LPAR4 | |
| SCHEMBL12582038 | 0.86 | LPAR1 (0.54) | LPAR1LPAR3LPAR2LPAR6LPAR4 | |
| SCHEMBL12348908 | 0.84 | LPAR1 (0.51) | LPAR1LPAR3LPAR2RECQLTLR2 | |
| SCHEMBL12348984 | 0.83 | P2RY10 (0.53) | LPAR1LPAR3LPAR2PLA2G2C | |
| SCHEMBL12345721 | 0.81 | LPAR3 (0.82) | LPAR1LPAR3LPAR2LPAR6LPAR4 | |
| SCHEMBL2232554 | 0.81 | LPAR3 (0.82) | LPAR1LPAR3LPAR2LPAR6LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195937-A1 | OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-08-11 | — | — | US | disclosed |
| WO-2010041242-A2 | OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195937-A1 | OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF | PRDX2, PRDX1, LPO | LPAR1 147/4885LPAR3 251/4885LPAR2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.